{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:13:21Z","timestamp":1787732001079,"version":"build-2784847793"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"Supplement_I","license":[{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The 2021 guidelines of the European Society of Cardiology on the diagnosis and therapy of heart failure (HF) introduced relevant changes in the pharmacological treatment of chronic HF. Among these, certainly the most significant was the introduction in the therapeutic flow-chart (with the highest recommendation level) of the sodium glucose co-transporter 2 (SGLT2) inhibitors. In fact, SGLT2 inhibitors are responsible for major paradigm shifts in the care of patients with or at high risk for HF, progression of chronic kidney disease, or both. SGLT2 inhibition demonstrated to improve cardiovascular outcomes in patients with HF over a wide range of ejection fractions, regardless of diabetic status, and have a strong nephroprotective effect. There are several important interactions between heart disease and kidneys disease. Indeed, acute or chronic dysfunction of the heart or kidneys can induce acute or chronic dysfunction in the other organ. The term \u2018cardiorenal syndrome\u2019 has been applied to these interactions. Since kidneys dysfunction in the setting of HF has a strong prognostic relevance, drugs that can slow down the decline of renal function are of utmost importance. Here, we discuss about the beneficial effects of SGLT2 inhibitors on the kidneys function in patients with HF and how these effects can improve both renal and cardiovascular outcomes.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suac101","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T15:20:53Z","timestamp":1668266453000},"page":"I68-I71","source":"Crossref","is-referenced-by-count":12,"title":["Sodium\u2013glucose co-transporter 2 inhibitors for the treatment of cardio-renal syndrome"],"prefix":"10.1093","volume":"24","author":[{"given":"Gennaro","family":"Cice","sequence":"first","affiliation":[{"name":"Department of Cardiology, Policlinico Casilino , Rome"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Calo\u2019","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Policlinico Casilino , Rome"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Monzo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Policlinico Casilino , Rome"},{"name":"Department of Clinical Internal, Anaesthesiological and Cardiovascular Sciences, Sapienza University , Rome"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,12]]},"reference":[{"key":"2022111417540123600_suac101-B1","first-page":"384","volume-title":"Congestive Heart Failure: Current Research and Clinical Applications.","author":"Braunwald","year":"1982"},{"key":"2022111417540123600_suac101-B2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-101-3-370","article-title":"The neurohumoral axis in congestive heart failure","volume":"101","author":"Francis","year":"1984","journal-title":"Ann Intern Med"},{"key":"2022111417540123600_suac101-B3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.15420\/cfr.2016:22:2","article-title":"Neurohormonal blockade in heart failure","volume":"3","author":"von Lueder","year":"2017","journal-title":"Card Fail Rev"},{"key":"2022111417540123600_suac101-B4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2010.165","article-title":"Epidemiology and risk profile of heart failure","volume":"8","author":"Bui","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"2022111417540123600_suac101-B5","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2022111417540123600_suac101-B6","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2022111417540123600_suac101-B7","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2022111417540123600_suac101-B8","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2022111417540123600_suac101-B9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41540-017-0013-4","article-title":"Mechanisms of action of sacubitril\/valsartan on cardiac remodeling: a systems biology approach","volume":"3","author":"Iborra-Egea","year":"2017","journal-title":"NPJ Syst Biol Appl"},{"key":"2022111417540123600_suac101-B10","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/eurjpc\/zwab034","article-title":"Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin","volume":"29","author":"Fontes-Carvalho","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2022111417540123600_suac101-B11","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2459\/JCM.0000000000001331","article-title":"What proportion of patients with heart failure and preserved ejection fraction are eligible for empagliflozin?","volume":"23","author":"Monzo","year":"2022","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2022111417540123600_suac101-B12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijcard.2021.08.035","article-title":"Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction","volume":"341","author":"Monzo","year":"2021","journal-title":"Int J Cardiol"},{"key":"2022111417540123600_suac101-B13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1161\/CIRCULATIONAHA.105.580506","article-title":"Renal function as a predictor of outcome in a broad spectrum of patients with heart failure","volume":"113","author":"Hillege","year":"2006","journal-title":"Circulation"},{"key":"2022111417540123600_suac101-B14","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"key":"2022111417540123600_suac101-B15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3389\/fphys.2013.00187","article-title":"Interactions between adenosine, angiotensin II and nitric oxide on the afferent arteriole influence sensitivity of the tubuloglomerular feedback","volume":"4","author":"Persson","year":"2013","journal-title":"Front Physiol"},{"key":"2022111417540123600_suac101-B16","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.3390\/ijms23073651","article-title":"An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors","volume":"23","author":"Salvatore","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2022111417540123600_suac101-B17","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","article-title":"Diabetic kidney disease","volume":"1","author":"Thomas","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2022111417540123600_suac101-B18","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/24\/Supplement_I\/I68\/47030536\/suac101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/24\/Supplement_I\/I68\/47030536\/suac101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T17:57:12Z","timestamp":1668448632000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/24\/Supplement_I\/I68\/6823825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,12]]},"references-count":18,"journal-issue":{"issue":"Supplement_I","published-online":{"date-parts":[[2022,11,12]]},"published-print":{"date-parts":[[2022,11,12]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suac101","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,12]]},"published":{"date-parts":[[2022,11,12]]}}}